Lenograstim

CLINICAL USE

Recombinant human granulocyte-colony stimulating factor (rHuG-CSF):Reduction of duration of neutropenia

DOSE IN NORMAL RENAL FUNCTION

Cytotoxic neutropenia: 150 mcg/m 2 (19.2 MIU/m2) daily SCMobilisation of peripheral blood progenitor cells: 10 mcg/kg (1.28 MIU/kg) dailyBone marrow transplant: 150 mcg/m 2 (19.2 MIU/m2) daily as an

IV infusion

PHARMACOKINETICS

Molecular weight :20 000

%Protein binding :No data

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :1

half-life – normal/ESRD (hrs) :3–4

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

Water for injection (1 mL)

Route

SC, IV

Rate of Administration

30 minutes

Comments

Dilute lenograstim-13.4 in up to 50 mL sodium chloride 0.9%Dilute lenograstim-33.6 in up to 100 mL sodium chloride 0.9%.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home